Last updated on April 2018

Safety and Efficacy of Lastacaft for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea


Brief description of study

This post-marketing surveillance study will assess the safety and efficacy of Lastacaft Opthalmic Solution 0.25% (Alcaftadine) for the prevention of itching associated with Allergic Conjunctivitis as prescribed as standard of care in clinical practice in Korea.

Clinical Study Identifier: NCT02555761

Contact Investigators or Research Sites near you

Start Over

Clinical Trials Registry Team

Onuri Eye Hospital
Jeollabuk-do, Korea, Republic of